Medicure Inc. (OTCMKTS:MCUJF – Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 3,348 shares, a decrease of 93.1% from the September 30th total of 48,345 shares. Based on an average trading volume of 26,042 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are short sold.
Medicure Trading Up 2.0%
Shares of OTCMKTS:MCUJF traded up $0.06 during trading hours on Wednesday, hitting $3.11. 2,175 shares of the company’s stock traded hands, compared to its average volume of 11,055. The firm has a market capitalization of $32.47 million, a P/E ratio of -6.10 and a beta of 1.13. The business has a fifty day moving average price of $2.02 and a 200-day moving average price of $1.12. Medicure has a 1 year low of $0.67 and a 1 year high of $3.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.97 and a quick ratio of 0.64.
Medicure (OTCMKTS:MCUJF – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%. The business had revenue of $5.36 million during the quarter, compared to the consensus estimate of $2.45 million.
Medicure Company Profile
Medicure Inc is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations.
Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.
Recommended Stories
- Five stocks we like better than Medicure
- Why Tesla’s Upside Is About More Than a SpaceX Merger
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
- Want to Own a Piece of Professional Sports? This ETF Could Be Your Ticket
- Welltower’s Strong Earnings Couldn’t Stop the Sell-Off—What’s Missing?
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
